Lilly to Expand Oncology Portfolio with Purchase of Loxo Oncology
- Posted by ISPE Boston
- On January 17, 2019
Eli Lilly and Loxo Oncology have announced a definitive agreement for Lilly to acquire Loxo for $235 per share in cash, or approximately $8.0 billion. Headquartered in Stamford, Connecticut, Loxo Oncology is a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers. The acquisition would be […]
Read More